Hjem › Endometriekreft › Oregon › Portland
Kliniske studier for Endometriekreft i Portland, OR
24 studier for Endometriekreft søker deltakere på steder i og rundt Portland (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RekruttererFase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekruttererFase 1/2
- Research Site, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Oregon Health & Science University (OHSU), Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RekruttererFase 1
- Site 02, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Portland
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RekruttererFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RekruttererFase 1
- Research Site, Portland
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RekruttererFase 2
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Providence Portland Medical Center, Portland
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RekruttererFase 3
- USOR - NW Cancer Specs P.C., Portland
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RekruttererFase 1
- Providence Cancer Institute of Oregon, Portland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Oregon Health and Science University, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
RekruttererFase 1
- Providence Cancer Institute, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Compass Oncology - Rose Quarter, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Oregon Health & Science University, Portland
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekruttererFase 3
- Research Site, Portland
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Investigative Site #121, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Providence Cancer Institute Franz Clinic, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Oregon Health Sciences University, Portland
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RekruttererFase 2
- Northwest Cancer Specialists, P.C., Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekruttererFase 1/2
- Oregon Health & Science University, Portland
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
RekruttererFase 2/3
- Northwest Cancer Specialists, Portland
Endometriekreft-studier i andre byer
- Houston, TX68 studier
- New York City, NY52 studier
- Boston, MA50 studier
- Arlington, VA39 studier
- Nashville, TN38 studier
- Los Angeles, CA34 studier
- St. Louis, MO29 studier
- Philadelphia, PA28 studier
- San Antonio, TX27 studier
- Columbus, OH25 studier
- Oklahoma City, OK25 studier
- Chicago, IL25 studier
Andre studier i Portland
- Ikke-småcellet lungekreft46 studier
- Kreft (alle typer)34 studier
- Brystkreft33 studier
- Prostatakreft33 studier
- Metastatisk kreft29 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Lungekreft26 studier
- Akut myelogen leukemi25 studier
- Plateepitelcancer i hode og hals19 studier
- Pankreaskreft19 studier
- Hjertesvikt17 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.